ABBV: 艾伯维

ABBV新闻

• 20:45 AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
• 20:27 The 13 Best S&P 500 Stocks to Buy Now, According to Barchart’s Screeners
• 15:00 Cyclicals Top Sectors In Wednesday Trading As Defensives Trail
• 15:00 周期性行业在周三交易中领涨，防御性行业落后
• 12:49 巴克莱维持对艾伯维的增持评级，将目标价上调至325美元
• 12:49 Barclays Maintains Overweight on AbbVie, Raises Price Target to $325
• 13:12 Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises
• 05:04 15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now
• 12:00 AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
• 12:00 Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie
• 08:05 AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease
• 08:05 艾伯维双靶点药物在难治性克罗恩病中显示出 II 期结果
• 07:01 周六报告：艾伯维表示，Rinvoq在第144周约四年时维持克罗恩病内镜缓解率达47.1%-64.2%；Skyrizi在UEGW上显示溃疡性结肠炎于第96周维持内镜缓解率达38.8%-53.5%
• 07:01 Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
• 06:51 据报道，艾伯维计划在ESMO 2026上更新数据，显示ABBV-706在二线及以上小细胞肺癌中实现56%的客观缓解率（ORR）和12.4个月的中位总生存期（OS），在仅二线患者中ORR为82%
• 06:51 Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
• 14:57 5 Stock Ideas for Your Short List
• 18:25 Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
• 17:57 AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO - TipRanks.com
• 15:22 AbbVie’s Q3 2026 Earnings: What to Expect
• 15:39 Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
• 15:39 纳斯达克100指数因高企CPI下跌1%，SOXX连续第7天下跌：今日股市
• 15:14 8 Of 11 Sectors Fall Wednesday As Defensives Lead
• 15:09 Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?